Skip to main content
. 2014 May 26;5(12):4337–4346. doi: 10.18632/oncotarget.2016

Figure 3. DQA and embelin treatment induces cell death in AML primary blasts by preferentially affecting LSC population and reduces clonogenic capacity.

Figure 3

AML primary blasts A. or healthy myeloid blood cells B. were treated with different concentration of DQA (0.05, 0.5, 5 μM) and embelin (0.1, 1, 10 μM). Cell viability was analysed at day 1 (upper panels) and 3 (lower panels) after treatment. Each symbol corresponds to a single AML patient sample, specified in the graph legend. Bulk population corresponds to AML blast cells and the primitive fraction corresponds to a CD34+CD38- blast population. C. Primary AML patient samples were treated for 24 h with 5 mM DQA. Cell viability was measured by flow cytometry (volumetric counts on live 7-AAD− cells). Each symbol corresponds to an AML patient sample. Green, favourable risk group; blue, intermediate risk group; red, unfavourable risk group. * p<0.05; ** p<0.005; *** p<0.0005.